Journal issues > Issue 3, September 2015 > Longer acting agents for the treatment of bleeding disorders

Longer acting agents for the treatment of bleeding disorders

summary

Concentrates of coagulation factors VIII and IX have good haemostatic effects on acute bleeding and during surgical intervention in patients with hemophilia A and B. However, the current agents used in this setting are mostly short-acting, making therapy troublesome for patients. Currently, new clotting factor concentrates are becoming available, or are in advanced clinical studies which will significantly improve the treatment for patients with hemophilia A and B. Various bioengineering concepts have been applied to modified recombinant FVIII, FIX and FVII proteins.¹ These different technologies were summarised in an educational presentation during the 2015 annual EHA meeting by Dr. Johannes Oldenburg (University Clinic Bonn, Germany).

(BELG J HEMATOL 2015;6(3):130–1)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top